Suboxone addiction: Symptoms, Side Effects, Withdrawal, and Treatments

Suboxone addiction develops when individuals misuse or overuse Suboxone, a medication prescribed for treating opioid use disorder. This drug combines two active components: buprenorphine and naloxone.

The signs and symptoms of Suboxone addiction include intense drug cravings, loss of control, compulsive use, shallow breathing, constricted pupils, continued use despite negative health effects, doctor shopping, social isolation, drug-seeking behaviors, and withdrawal symptoms when the medication is stopped.

Side effects of Suboxone addiction can involve dizziness, cough, fever, skin reactions like redness or swelling, urinary difficulties, excessive sweating, trouble sleeping, and chronic headaches. Other common issues include constipation, blurred vision, nausea, vomiting, and potential long-term liver damage.

Withdrawal from Suboxone presents symptoms such as irritability, nausea, vomiting, diarrhea, muscle pain, dilated pupils, depression, and anxiety. Individuals may also suffer from chills, fever, headaches, digestive problems, insomnia, and intense drug cravings.

Treatment options for Suboxone addiction typically include medically supervised detoxification, a gradual reduction in dosage, medication-assisted treatment, behavioral therapy, participation in support groups, and ongoing aftercare to prevent relapse.

Is Suboxone addictive?

Yes, Suboxone can be addictive because it contains buprenorphine, a partial opioid agonist. When misused or taken without proper medical guidance, buprenorphine can lead to dependence and addiction.

Buprenorphine’s potential for abuse arises from its action on opioid receptors, though its abuse potential is lower than that of full opioid agonists. Despite its reduced abuse potential, buprenorphine can still lead to physical dependence. When used improperly or over-extended periods, the body may become accustomed to the drug, and sudden cessation or a significant reduction in dosage can trigger withdrawal symptoms, such as irritability, nausea, muscle aches, and cravings, similar to withdrawal from other opioids.

This is why caution is emphasized in the Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (2004) by the Center for Substance Abuse Treatment, published by the Substance Abuse and Mental Health Services Administration (SAMHSA). The guidelines stress that healthcare providers must closely monitor patients using Suboxone, particularly in combination with naloxone, to guard against medication diversion. Providers should also be cautious of potential interactions with benzodiazepines, opioid antagonists, and other sedatives.

How addictive is Suboxone?

Suboxone has a moderate potential for addiction if misused or taken outside the prescribed guidelines. In 2022, the Drug Enforcement Administration (DEA) classified Suboxone as a Schedule III controlled substance, indicating it carries a moderate to low risk of physical or psychological dependence, as outlined in the DEA Diversion Control Division Drug & Chemical Evaluation Section “BUPRENORPHINE (Trade Names: Buprenex®, Suboxone®, Subutex®, Zubsolv®, Sublocade®, Butrans®),” published in May 2022.

The combination of buprenorphine with naloxone was specifically designed to lower the potential for abuse, particularly through injection. However, as the 2004 “Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction” by the Center for Substance Abuse Treatment (SAMHSA) highlights, Suboxone is not entirely free from addictive properties.

How likely is Suboxone to cause addiction?

Suboxone has addictive potential because it contains buprenorphine, a partial opioid agonist. This means it activates the same brain receptors as opioids, though to a lesser extent.

When misused, buprenorphine can lead to moderate physical dependence or strong psychological dependence, as noted in the Drugs.com article on “Buprenorphine,” updated in August 2023. This risk is especially high in individuals with a history of substance abuse, where misuse can result in addiction, overdose, or even death, as the article emphasizes.

A 2020 study by Blazes CK. and Morrow JD., “Reconsidering the Usefulness of Adding Naloxone to Buprenorphine,” highlights the addition of naloxone to buprenorphine to lower the risk of diversion and improper use.

However, the effectiveness of naloxone in preventing Suboxone diversion has been debated, as discussed in the 2022 Frontiers in Psychiatry article, "Suboxone: History, controversy, and open questions." The FDA label for Suboxone indicates that naloxone has a half-life of 2 to 12 hours, while buprenorphine’s half-life ranges from 24 to 42 hours.

This discrepancy suggests that naloxone’s antagonist effects may wear off before buprenorphine’s agonistic effects, potentially allowing individuals to experience the pleasurable effects of buprenorphine. Over time, this repeated exposure can lead to sensitization, reinforcing subconscious drug-seeking behavior.

How common is Suboxone addiction?

Suboxone addiction is relatively rare, with approximately 690,000 individuals, about 0.2% of the U.S. population aged 12 and older, reporting misuse of buprenorphine products, including Suboxone, within the past year. This data comes from the Substance Abuse and Mental Health Services Administration (SAMHSA) 2021 report, “Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health.”

Additionally, the Centers for Disease Control and Prevention's “Medications for Opioid Use Disorder Study (MOUD Study),” last revised in January 2022, states that approximately 2.1 million people in the U.S. suffer from opioid use disorder (OUD) linked to prescription opioids, which may include buprenorphine.

These statistics, along with the recognition of Suboxone's addictive potential, highlight the ongoing challenge of addressing and preventing the misuse and potential addiction of this medication.

What is another term for Suboxone addiction?

Another term for Suboxone addiction is buprenorphine addiction. Since buprenorphine is the active ingredient in Suboxone, dependence or misuse of this medication is commonly referred to as buprenorphine addiction.

Many individuals using buprenorphine mistakenly believe it is a milder opioid and therefore less likely to cause addiction compared to stronger opioids like methadone. However, regardless of its potency, all controlled substances, including buprenorphine, have the potential for abuse, dependence, and addiction, as noted in the “Drugs of Abuse: A DEA Resource Guide,” published by the Drug Enforcement Administration in 2020.

What are the symptoms and signs of Suboxone addiction?

Suboxone addiction is characterized by a combination of physical, behavioral, and psychological symptoms, which vary in intensity. Below are the common signs of Suboxone addiction:

• Drug cravings: Persistent and intense urges to use Suboxone highlight the individual’s psychological dependence on the drug. These cravings drive compulsive behavior, where the individual seeks out Suboxone despite negative consequences.
  
  
• Loss of control: An inability to manage the amount or frequency of Suboxone use, even when trying to reduce or stop, signals a loss of control, a hallmark of addiction.
  
  
• Compulsive use: The uncontrollable and persistent use of Suboxone, regardless of adverse effects on personal, professional, or social life, is a clear sign of addiction.
  
  
• Slow breathing: Hypoventilation, or slow breathing, occurs due to the central nervous system depressant effects of buprenorphine in Suboxone. When abused, Suboxone can exaggerate these effects, reducing the breathing rate.
  
  
• Pinpoint pupils: Constricted pupils, or pinpointing, is a common physiological reaction to opioids. Buprenorphine in Suboxone causes the muscles controlling pupil size to contract, leading to smaller pupils that do not adjust well to changes in light.
  
  
• Continued use despite health problems: Continuing to use Suboxone despite experiencing physical or psychological health issues reflects a disregard for the harm caused by the drug, further indicating addiction.
  
  
• Doctor shopping: Engaging in deceitful practices to obtain more Suboxone, such as seeking prescriptions from multiple healthcare providers, is a clear sign of addiction. A 2023 study by Soeiro T. et al. highlighted that opioids, including buprenorphine, were among the most commonly abused prescription drugs through doctor shopping.
  
  
• Social withdrawal: Suboxone addiction often leads to isolation and neglect of responsibilities, as the individual becomes increasingly withdrawn from social and recreational activities once enjoyed.
  
  
• Drug-seeking behavior: Individuals may devote significant time and effort to acquire, use, and recover from Suboxone's effects. This obsessive behavior is characteristic of addiction, reflecting a compulsive drive for the substance.
  
  
• Withdrawal symptoms upon cessation: Discomfort and distress upon abruptly stopping or reducing Suboxone use are signs of addiction. Withdrawal symptoms, which resemble those of opioid withdrawal, can include anxiety, depression, gastrointestinal distress (e.g., diarrhea, abdominal pain), nausea, vomiting, headaches, and fatigue, as described in a March 2023 article on Drugs.com titled “How long does Suboxone withdrawal last?”

These signs collectively point to the presence of Suboxone addiction and underline the need for professional intervention to manage and treat the condition effectively.

What are the causes of Suboxone addiction?

The causes of Suboxone addiction are multifaceted, involving a combination of physiological, psychological, and environmental factors.

Here are the key potential causes of Suboxone addiction:

• Opioid dependence treatment: Suboxone is frequently prescribed to treat opioid dependence. However, addiction can develop when the medication is misused, taken in higher doses than prescribed, or used without appropriate medical supervision during the treatment process.
  
  
• Misuse or self-medication: The risk of addiction increases when Suboxone is misused, such as taking larger doses or using it without a prescription for self-medication or to induce euphoria. A 2021 study published in JAMA Network Open, titled “Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US,” found that many individuals misused buprenorphine as a means of managing cravings and relieving withdrawal symptoms associated with opioid use disorder (OUD).
  
  
• History of childhood trauma and abuse: Individuals with a history of trauma or abuse are more susceptible to developing addiction, including to Suboxone. As noted in the National Library of Medicine’s article on "Opioid Use Disorder" (July 2023), people with past abuse often use substances to cope, making them more vulnerable to addiction due to past adverse experiences.
  
  
• Genetic predisposition: Research from the National Institute on Drug Abuse (NIDA), published in March 2023, indicates that genetic factors and complex interactions between genes and the environment influence addiction. Individuals with a family history of addiction are at higher risk of developing substance use disorders (SUD), including addiction to Suboxone.
  
  
• Co-occurring mental health disorders: Mental health conditions, such as depression or anxiety, often coincide with substance abuse. People with these conditions are at a higher risk of developing addiction to Suboxone, as highlighted in SAMHSA’s “Co-Occurring Disorders and Other Health Conditions” (July 2023).
  
  
• Environmental factors: Exposure to environments where substance abuse is prevalent, a lack of social support, or experiencing stressful life events can increase the risk of Suboxone addiction.
  
  
• Availability and accessibility: The easy availability of Suboxone and the relatively simple process of obtaining prescriptions can contribute to the risk of addiction, particularly when the medication is not used under proper medical supervision.

Each of these factors can interact to create a perfect storm that increases the risk of Suboxone addiction, highlighting the importance of proper use, medical supervision, and addressing underlying mental health and environmental influences.

How long does it take to get addicted to Suboxone?

The time it takes to develop an addiction to Suboxone can vary based on factors such as individual susceptibility, dosage, frequency of use, and whether the medication is taken as prescribed. For most people using Suboxone properly under medical supervision for opioid use disorder (OUD), the risk of addiction is minimized.

However, when Suboxone is misused, by taking higher doses, using it more frequently than prescribed, or using it without medical supervision, addiction can develop within a few weeks to a few months. Individuals who misuse Suboxone may start to experience dependence and addiction symptoms in as little as 7 to 30 days of improper use.

Buprenorphine, the active ingredient in Suboxone, acts on opioid receptors in the brain. With repeated misuse, tolerance can develop quickly, requiring higher doses for the same effect, which can lead to physical dependence and psychological addiction. As misuse continues, signs of addiction, such as drug cravings, loss of control, and compulsive use, may become evident within the first few weeks.

If Suboxone use is stopped or reduced suddenly, withdrawal symptoms, such as irritability, nausea, muscle aches, and cravings, can begin within 12-24 hours and may persist for days or even weeks. These withdrawal symptoms are a key indicator of physical dependence and addiction.

What are the side effects of Suboxone addiction?

The side effects of Suboxone addiction can affect various systems in the body. These effects can be both short-term and long-term, depending on the duration and intensity of misuse. Below is a breakdown of the common side effects:

Short-term side effects:

• Feeling faint, dizzy, or lightheaded: Suboxone acts as a central nervous system depressant, leading to dizziness and lightheadedness. These symptoms are linked to the drug’s impact on balance and coordination, which are vital for maintaining posture.
  
  
• Cough: The depressant action of Suboxone on the respiratory system can impair normal lung function, leading to persistent coughing.
  
  
• Fever: Fever can develop as a result of infections caused by unsafe drug use practices, such as improper injection. Suboxone misuse may also interact with other substances, contributing to this side effect.
  
  
• Sweating: Excessive sweating can occur due to Suboxone’s influence on the autonomic nervous system. This can disrupt normal body temperature regulation and lead to abnormal perspiration.
  
  
• Nausea and vomiting: Suboxone can irritate the stomach lining, affecting the brain’s vomiting center, leading to nausea, loss of appetite, and vomiting.
  
  
• Urinary issues: Misuse of Suboxone may cause urinary retention, resulting in difficulty initiating urination or emptying the bladder completely.
  
  
• Difficulty sleeping: Suboxone can disrupt normal brain chemistry, causing insomnia or difficulty falling asleep.

Long-term side effects:

• Headache: Long-term use of Suboxone can lead to persistent or severe headaches due to changes in blood flow and brain chemistry.
  
  
• Constipation: As an opioid, Suboxone slows down the digestive system, leading to constipation and difficulty with bowel movements.
  
  
• Abnormal vision: Long-term use of Suboxone may affect the nervous system, causing visual disturbances, including blurred vision.
  
  
• Reduced sex drive: The opioid content in Suboxone can suppress the production of sex hormones, leading to a decreased libido.
  
  
• Pain in the chest, stomach, back, muscles, and joints: Suboxone’s impact on the central nervous system can alter pain perception pathways, resulting in discomfort in various body areas.
  
  
• Liver damage: Prolonged misuse of Suboxone places a strain on the liver, as the buprenorphine component is metabolized there. Over time, this can result in liver toxicity, especially in individuals more sensitive to the drug.

Overall, these side effects reflect the broad and varying impacts of Suboxone addiction on the body. Short-term side effects primarily affect daily functioning, while long-term misuse can lead to more severe, persistent health problems that require medical intervention. Addressing addiction early and seeking treatment can help prevent or mitigate these risks.

How dangerous is Suboxone addiction for pregnant women?

Suboxone addiction during pregnancy poses significant risks to both the mother and the developing fetus. While Suboxone is often prescribed as part of medication-assisted treatment (MAT) for opioid use disorder (OUD) during pregnancy, misuse or addiction to Suboxone can lead to serious complications. Here are the side effects of Suboxone addiction on pregnant women:

• Miscarriage: Misuse of Suboxone during pregnancy can increase the risk of miscarriage, especially in the first trimester. The physical stress placed on the body by opioid misuse, including the potential for withdrawal symptoms, can destabilize the pregnancy and cause a higher risk of pregnancy loss.
  
  
• Preterm labor: Suboxone addiction can increase the likelihood of preterm labor, potentially leading to early delivery. Preterm birth is associated with a range of complications for the baby, including underdevelopment of vital organs and low birth weight.
  
  
• Neonatal Abstinence Syndrome (NAS): Babies born to mothers with Suboxone addiction may experience neonatal abstinence syndrome (NAS), a condition where the newborn experiences withdrawal symptoms after birth. NAS symptoms can include tremors, irritability, poor feeding, vomiting, diarrhea, and difficulty sleeping. NAS requires immediate medical attention and treatment to manage these withdrawal symptoms.
  
  
• Respiratory problems: Suboxone’s central nervous system depressant effects can lead to respiratory depression, which may be exacerbated during pregnancy. In addition to the risks of withdrawal, this can lead to difficulties with breathing in both the mother and the baby, further complicating the pregnancy.
  
  
• Low birth weight and developmental issues: Babies exposed to Suboxone addiction during pregnancy may be at risk of low birth weight, which can lead to further developmental delays. Studies have shown that babies born to mothers with opioid addiction, including those on Suboxone, may experience cognitive and behavioral challenges later in life, including problems with attention, learning, and emotional regulation.
  
  
• Placental problems: Opioid misuse during pregnancy can lead to placental abruption, a condition where the placenta detaches from the uterine wall before delivery. This can cause severe bleeding and deprive the baby of oxygen and nutrients, putting both mother and baby at risk.
  
  
• Withdrawal symptoms in the mother: Suboxone addiction during pregnancy can also lead to severe withdrawal symptoms in the mother, including anxiety, depression, nausea, vomiting, and gastrointestinal distress. These symptoms can negatively impact the mother's health and her ability to care for herself and her baby.

While Suboxone can be a crucial part of treating opioid use disorder during pregnancy, it must be used under strict medical supervision. Healthcare providers often recommend using Suboxone at the lowest effective dose to minimize the risk to both the mother and the baby. Additionally, comprehensive prenatal care, including monitoring for signs of complications and providing counseling and support, is essential for ensuring a healthy pregnancy and a safer outcome for the baby.

Can Suboxone alter personality?

Yes, Suboxone can indirectly influence personality, leading to variations in how individuals respond emotionally. These changes can include increased sociability or extroversion, as well as instances of heightened withdrawal and introversion. The extent and nature of these changes vary among individuals, depending on how the medication interacts with the brain.

While some people report mood or personality shifts during Suboxone treatment, it’s important to recognize that these changes cannot be attributed solely to the medication. Suboxone is typically prescribed during pivotal moments in a person’s life, especially when they commit to recovery, which can lead to a wide range of emotional experiences. These can include negative mood changes or, conversely, feelings of success and improved emotional well-being associated with abstaining from drug use.

It is crucial to consider that mood changes, such as fatigue, anxiety, or irritability, are often linked to the broader process of quitting drugs and the significant lifestyle changes that accompany recovery. Determining whether these shifts are due to Suboxone or other life factors is difficult, given the complex and multifactorial nature of mood and personality.

The potential indirect effects of buprenorphine on personality were explored in a 2008 study by Sansone RA et al., titled “The Prevalence of Borderline Personality Among Buprenorphine Patients”, published in the International Journal of Psychiatry in Medicine. The study found that borderline personality disorder (BPD) was more prevalent among individuals receiving buprenorphine treatment for opioid addiction.

BPD is a psychiatric disorder that significantly impairs emotional regulation, leading to increased impulsivity, distorted self-image, and challenges in interpersonal relationships. Individuals undergoing Suboxone or buprenorphine treatment may experience altered emotional responses, particularly exaggerated reactions to negative stimuli and reduced responses to positive experiences.

Is it possible to overdose on Suboxone?

Yes, it is possible to overdose on Suboxone, particularly if taken in excessive amounts or combined with other substances such as alcohol or benzodiazepines.

According to Medsafe’s consumer medicine information on “SUBOXONE® Sublingual Tablets” (last updated in July 2021), while Suboxone is prescribed for managing opioid dependence, it carries a risk of misuse, which can result in overdose and potentially fatal consequences.

The risk of overdose is higher in individuals without a history of opioid use, older adults, or those who combine Suboxone with alcohol, benzodiazepines, or other medications, as noted in the Drugs.com article titled “Can You Overdose on Suboxone?” (last revised in March 2023).

Symptoms of a Suboxone overdose include irregular, fast, slow, or shallow breathing, extreme drowsiness, confusion, unusual tiredness or weakness, and dizziness or faintness when standing up quickly from a sitting or lying position, as detailed in the Drugs.com article “Suboxone Side Effects” (updated in August 2023). Additional overdose symptoms can include blurred vision, pale or blue lips, fingernails, or skin, and pinpoint pupils.

In severe cases, an overdose on Suboxone can lead to seizures, coma, and even death. It is essential to take Suboxone strictly as prescribed by a healthcare provider and to disclose any other medications or substances being used to minimize the risk of overdose.

What are the symptoms of Suboxone withdrawal?

The symptoms of Suboxone withdrawal include irritability, nausea, vomiting, diarrhea, muscle aches, dilated pupils, depression, and anxiety. These symptoms typically emerge when individuals who are dependent on Suboxone suddenly reduce their dosage or stop using it altogether.

The withdrawal process usually follows a predictable pattern. In the first 72 hours, individuals may experience physical symptoms such as chills, fever, headaches, gastrointestinal issues, and insomnia, as noted in the Drugs.com article “How long does Suboxone withdrawal last?” (last updated in March 2023).

In the following days, muscle aches, persistent insomnia, and mood swings often continue. After about two weeks, symptoms of depression become more prominent, and drug cravings typically begin.

Suboxone withdrawal symptoms usually last around a month, though the duration can vary depending on factors like the length of Suboxone use, dosage levels, co-existing medical conditions, and alcohol consumption.

For individuals considering discontinuation or detoxification from Suboxone, it is crucial to do so under the supervision of a healthcare professional. Gradual tapering, along with the use of specific medications and behavioral therapies, can help manage withdrawal symptoms and improve the chances of a successful recovery.

What treatment options are available for Suboxone addiction?

Treating Suboxone addiction requires a multifaceted approach that addresses both the physical dependence and the underlying psychological factors contributing to the addiction. Below are the key treatment options for Suboxone addiction:

• Medically assisted detoxification (detox): Detoxification is a crucial initial step in treating Suboxone addiction. It focuses on safely managing withdrawal symptoms and ensuring physical stability. Medically supervised detox ensures that withdrawal symptoms are properly addressed and the patient’s safety and comfort are prioritized. This phase serves as a gateway to further comprehensive treatment.
  
  
• Gradual tapering: A gradual tapering process is often employed to reduce the intensity of withdrawal symptoms. A 2013 study, “A Randomized, Double-blind Evaluation of Buprenorphine Taper Duration in Primary Prescription Opioid Abusers,” published in JAMA Psychiatry, found that a 4-week tapering regimen resulted in better outcomes, including higher retention rates and improved adherence to treatment. Gradual tapering helps manage withdrawal more effectively compared to shorter regimens.
  
  
• Medication-assisted treatment (MAT): Medication-assisted treatment for Suboxone addiction involves using FDA-approved medications along with counseling and behavioral therapies. A 2020 study by Maglione MA. et al. explored MAT for opioid use disorder (OUD) and highlighted its effectiveness in managing Suboxone addiction. Medications like methadone and naltrexone are commonly used under medical supervision. Methadone helps manage withdrawal symptoms and supports detox, while naltrexone works to prevent relapse.
  
  
• Behavioral therapies: Behavioral therapies, particularly cognitive-behavioral therapy (CBT), have proven effective in treating Suboxone addiction. A 2020 study by Ray LA. et al., “Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders,” found that combining CBT with pharmacotherapy was more effective than either approach alone. CBT helps individuals address negative thought patterns and develop coping strategies, which are essential for maintaining long-term recovery.
  
  
• Support groups: Support groups like Narcotics Anonymous (NA) and other 12-step programs provide a valuable network of individuals who share similar experiences and challenges. These groups offer emotional support, motivation, and a sense of community, all of which contribute to the emotional and psychological aspects of Suboxone addiction recovery.
  
  
• Aftercare and relapse prevention: Aftercare is a critical component of long-term recovery, offering ongoing support after the initial treatment phase. This includes regular medical check-ups, monitoring of medication, lifestyle counseling, and peer support. A comprehensive approach that combines medication management with robust aftercare programs significantly improves quality of life and reduces the risk of relapse, providing a foundation for sustained recovery.
  
  

Each of these treatment options works together to help individuals manage their addiction, improve their well-being, and promote long-term recovery. It is important for those undergoing Suboxone addiction treatment to seek professional guidance to ensure the best possible outcome.

What is Suboxone used for?

Suboxone is primarily used to treat opioid dependence. It is part of a comprehensive medical, social, and mental treatment plan designed to suppress opioid withdrawal symptoms and reduce cravings for opioids, as outlined in Medsafe's consumer medicine information on “SUBOXONE® Sublingual Tablets” (last updated in July 2021).

In 2018, the FDA approved the first generic versions of Suboxone sublingual film, as mentioned in the document “FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence.” This approval aimed to increase access to opioid dependence treatment. The document highlighted that individuals undergoing medication-assisted treatment (MAT) for opioid use disorder (OUD) experience a 50% reduction in the risk of death from all causes.

Why is Suboxone used to treat opioid use disorder (OUD)?

Suboxone is effective in treating opioid use disorder (OUD) because it contains buprenorphine, a partial opioid agonist. Buprenorphine reduces cravings and withdrawal symptoms without inducing intense euphoria. Naloxone, the other component of Suboxone, discourages misuse and blocks the effects of other opioids.

According to the World Health Organization (WHO) in the 2009 “Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence,” buprenorphine’s partial agonist activity means it does not cause opioid tolerance to the same extent as methadone. Additionally, it has a high receptor affinity, allowing it to block opioid effects without causing the same level of tolerance associated with methadone.

The slow dissociation of buprenorphine from receptors contributes to a milder withdrawal syndrome compared to methadone. As noted in the Center for Substance Abuse Treatment’s 2004 “Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction” from the Substance Abuse and Mental Health Services Administration (SAMHSA), one of the key advantages of buprenorphine or its formulation, Suboxone, is its safety. Its partial agonist action creates a “ceiling effect,” which significantly lowers the risk of overdose compared to opioids like methadone.

What is medication-assisted treatment (MAT)?

Medication-assisted treatment (MAT) is a therapeutic approach that combines medications with counseling and behavioral therapies to treat substance use disorders, particularly opioid use disorders. MAT supports individuals in maintaining their recovery and is recognized for its effectiveness in helping people manage addiction, as defined by the United States Food & Drug Administration in the article “Information about Medication-Assisted Treatment (MAT)” (last updated in May 2023).

According to this article, the FDA has approved three medications for opioid dependence treatment: buprenorphine, methadone, and naltrexone, due to their proven safety and effectiveness.

A 2020 randomized study titled “Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice,” published in the Journal of Primary Care & Community Health, found that individuals diagnosed with opioid use disorder (OUD) who were treated with either methadone or Suboxone showed a 33.2% abstinence rate from heroin and a 20.7% abstinence rate from all opioids over a five-year period. The study also reported that MAT led to a 51% reduction in the use of emergency department services.

MAT is an evidence-based method that supports individuals in their recovery journey. By integrating medication with a personalized treatment plan, MAT helps individuals address their addiction and work toward long-term recovery.

How does Suboxone addiction compare to methadone addiction?

Suboxone and methadone differ significantly in composition, effects, potential for misuse, and treatment protocols.

Suboxone combines buprenorphine, a partial opioid agonist, with naloxone, an opioid antagonist. This combination reduces misuse potential since naloxone counteracts euphoria if injected. Suboxone is taken sublingually, making it harder to misuse. In contrast, methadone, a full opioid agonist, produces stronger effects and is dispensed orally at specialized clinics. Methadone is classified as a Schedule II controlled substance, indicating a higher risk of misuse and addiction compared to Suboxone, which is a Schedule III controlled substance.

Suboxone tends to have milder withdrawal symptoms than methadone, as methadone’s full agonist action can lead to more intense withdrawal, especially at higher doses. Buprenorphine in Suboxone also has a “ceiling effect,” meaning its effects plateau at higher doses, reducing the risk of overdose. Methadone lacks this effect, making it more prone to overdose when misused.

Suboxone offers more flexibility since it can be prescribed and administered in a physician’s office, whereas methadone typically requires daily visits to treatment centers. Additionally, Suboxone has a longer half-life (36-48 hours) compared to methadone (24-36 hours), allowing for less frequent dosing.

Subutex, which contains only buprenorphine and no naloxone, is stronger than Suboxone in terms of opioid effects. Without naloxone, Subutex can be misused more easily and is more addictive. However, Suboxone is generally preferred due to naloxone’s deterrent effect on misuse.

Overall, methadone is more addictive than Suboxone due to its full opioid agonist properties and the lack of a ceiling effect. Suboxone’s combination of buprenorphine and naloxone makes it less likely to be misused and more suitable for long-term treatment.

‍